Спайдер повышается перед открытием торгов на NYSE.
Европейские индексы на отрицательной территории.
SPY (внутридневной график) рост движение на премаркете. Сопротивление: 166.20 Поддержка: 165.80
Премаркет NYSE/NASDAQ:
Gapping up:
• In reaction to stong earnings/guidance/SSS data: ENVI +28.6%, FCEL +15.4%, SIGM +9.1%, DDC +2.1%, COST +1.3%, WAG +1.3%.
• M&A news: KDN +21.3% (to be acquired by SKF for $35.50 per share), LPX +9.1% (to acquire Ainsworth for ~$1.1 bln, upgraded to Buy from Hold at Deutsche Bank, upgraded to Buy at DA Davidson), TI +8.1% (AT&T (T), American Movill (AMX), and Naguib Sawiris have approached key shareholders who want to exit stakes in TI, according to reports), BBRY +2.8% (following late spike on M&A speculation), ASTX +2.3% (Astex Pharma to be acquired by Otsuka Pharma for $8.50 per share in cash), VOD +1.8% (Dealbook discusses VZ's efforts to secure financing for Vodafone (VOD) deal), VZ +0.5%.
• Select India related names showing strength: HDB +6.3%, IBN +6%, TTM +2.7%.
• Other news: LOCM +39% (signs agreement with Microsoft (MSFT) to provide location-based local product data for Bing ), CLWT +18.7% (Reports Contract Awarded to PACT), MDXG +15.8% (following yesterday's sell-off; to hold conference call to discuss FDA 'Untitled Letter' and reiterate guidance on Thursday, September 5, 2013 at 11 am Eastern Time ), POZN +15.3% (POZEN and Sanofi (SNY) sign exclusive licence agreement for the commercialization of PA8140/PA32540 tablets in the U.S.), CHTP +6.8% (announces FDA Acceptance of NORTHERA (droxidopa) NDA Resubmission), IDCC +5.6% (related to ITC decision to review ruling in case against Nokia and other parties), HIMX +5.4% (target raised to $12 at Oppenheimer on better LCoS outlook), ALU +3.6% (reached an agreement with Telefonica, to become a reference supplier for its 4G LTE network in Spain), AU +2.3% (still checking), MRLN +2.1% (Declares Special Dividend of $2.00/share), NOK +1.9% (still checking, was resumed with an Equal-Weight at Morgan Stanley), CELG +1.5% (reports postive results from from Phase III study).
• Analyst comments: OVAS +6.2% (initiated with and Outperform at Wedbush), GRPN +5.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), YY +4.1% (upgraded to Outperform at Pacific Crest; tgt $52), ONB +2% (upgraded to Strong Buy from Outperform at Raymond James), SI +1.6% (upgraded to Overweight from Equal-Weight at Barclays), RIG +1.5% (upgraded to Outperform from Neutral at Credit Suisse), OMC +1.1% (upgraded to Buy from Neutral at Lazard), GMCR +0.9% ( tgt to $95 from $89 at Canaccord Genuity).
Gapping down:
• In reaction to disappointing earnings/guidance/SSS: CONN -12.3%, NCS -11.7%, BV -10.2%, EXA -8.2%, (thinly traded), MIND -7.2%, TITN -5.1%, GEF -4.8%.
• Other news: AGEN -33.8% (GlaxoSmithKline's (GSK) MAGE-A3 Cancer Immunotherapeutic Phase 3 study in melanoma misses first co-primary endpoint), CPRX -7.2% (Registration Statement filed for additional $2,612,336 aggregate maximum principal amount of common stock), LNKD -1.8% (prices 5,381,166 shares of Class A common stock at $223.00 per share), CCL -1% (cont weakness), GSK -1% ( independent analysis of the DERMAi study showed that the study did not meet its first co-primary endpoint).
• Analyst comments: Z -2.5% (downgraded to Underweight from Equal-Weight at Morgan Stanley), E -1.0% (downgraded to Neutral from Buy at Nomura).
Интересные новостные акции NYSE и NASDAQ:
• FRAN – смотрим акцию на разворот выше 18.00
• LNKD – шорт ниже 234.00
• LPX – шорт ниже 16.40
• CON – шорт ниже минимума премаркета
Оригинал статьи: shark-traders.com/blog/analitika-nyse-na-5-sentyabrya/
<a href="http://www.blogberg.ru"><img src="http://www.blogberg.ru/markup/images/logo_small.png" width="133" height="28" border="0" alt="Blogberg" /></a>
<div style="padding-left: 13px;">
<a href="http://blogberg.ru/blog/45205.html" style="color: #010101; font-weight: bold; font-family: 'Trebuchet MS', sans-serif; font-size: 24px; text-decoration: underline">Аналитика NYSE на 5 сентября</a><br />
<span style="color: #787878; font-family: 'Trebuchet MS', sans-serif; font-size: 13px">5 сентября 2013, 16:52</span><br />
<div style="color: #3d3d3d; padding-top: 10px; overflow: hidden; font-size: 13px; font-family: 'Trebuchet MS', sans-serif;">Спайдер повышается перед открытием торгов на NYSE. <br/>
Европейские индексы на отрицательной территории. <br/>
SPY (внутридневной график) рост движение на премаркете. Сопротивление: 166.20 Поддержка: 165.80 <br/>
Премаркет NYSE/NASDAQ:<br/>
Gapping up: <br/>
• In reaction to stong earnings/guidance/SSS data: ENVI +28.6%, FCEL +15.4%, SIGM +9.1%, DDC +2.1%, COST +1.3%, WAG +1.3%. <br/>
• M&A news: KDN +21.3% (to be acquired by SKF for $35.50 per share), LPX +9.1% (to acquire Ainsworth for ~$1.1 bln, upgraded to Buy from Hold at Deutsche Bank, upgraded to Buy at DA Davidson), TI +8.1% (AT&T (T), American Movill (AMX), and Naguib Sawiris have approached key shareholders who want to exit stakes in TI, according to reports), BBRY +2.8% (following late spike on M&A speculation), ASTX +2.3% (Astex Pharma to be acquired by Otsuka Pharma for $8.50 per share in cash), VOD +1.8% (Dealbook discusses VZ's efforts to secure financing for Vodafone (VOD) deal), VZ +0.5%. <br/>
• Select India related names showing strength: HDB +6.3%, IBN +6%, TTM +2.7%. <br/>
• Other news: LOCM +39% (signs agreement with Microsoft (MSFT) to provide location-based local product data for Bing ), CLWT +18.7% (Reports Contract Awarded to PACT), MDXG +15.8% (following yesterday's sell-off; to hold conference call to discuss FDA 'Untitled Letter' and reiterate guidance on Thursday, September 5, 2013 at 11 am Eastern Time ), POZN +15.3% (POZEN and Sanofi (SNY) sign exclusive licence agreement for the commercialization of PA8140/PA32540 tablets in the U.S.), CHTP +6.8% (announces FDA Acceptance of NORTHERA (droxidopa) NDA Resubmission), IDCC +5.6% (related to ITC decision to review ruling in case against Nokia and other parties), HIMX +5.4% (target raised to $12 at Oppenheimer on better LCoS outlook), ALU +3.6% (reached an agreement with Telefonica, to become a reference supplier for its 4G LTE network in Spain), AU +2.3% (still checking), MRLN +2.1% (Declares Special Dividend of $2.00/share), NOK +1.9% (still checking, was resumed with an Equal-Weight at Morgan Stanley), CELG +1.5% (reports postive results from from Phase III study). <br/>
• Analyst comments: OVAS +6.2% (initiated with and Outperform at Wedbush), GRPN +5.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), YY +4.1% (upgraded to Outperform at Pacific Crest; tgt $52), ONB +2% (upgraded to Strong Buy from Outperform at Raymond James), SI +1.6% (upgraded to Overweight from Equal-Weight at Barclays), RIG +1.5% (upgraded to Outperform from Neutral at Credit Suisse), OMC +1.1% (upgraded to Buy from Neutral at Lazard), GMCR +0.9% ( tgt to $95 from $89 at Canaccord Genuity).<br/>
Gapping down: <br/>
• In reaction to disappointing earnings/guidance/SSS: CONN -12.3%, NCS -11.7%, BV -10.2%, EXA -8.2%, (thinly traded), MIND -7.2%, TITN -5.1%, GEF -4.8%. <br/>
• Other news: AGEN -33.8% (GlaxoSmithKline's (GSK) MAGE-A3 Cancer Immunotherapeutic Phase 3 study in melanoma misses first co-primary endpoint), CPRX -7.2% (Registration Statement filed for additional $2,612,336 aggregate maximum principal amount of common stock), LNKD -1.8% (prices 5,381,166 shares of Class A common stock at $223.00 per share), CCL -1% (cont weakness), GSK -1% ( independent analysis of the DERMAi study showed that the study did not meet its first co-primary endpoint). <br/>
• Analyst comments: Z -2.5% (downgraded to Underweight from Equal-Weight at Morgan Stanley), E -1.0% (downgraded to Neutral from Buy at Nomura).<br/>
Интересные новостные акции NYSE и NASDAQ: <br/>
• FRAN – смотрим акцию на разворот выше 18.00 <br/>
• LNKD – шорт ниже 234.00 <br/>
• LPX – шорт ниже 16.40 <br/>
• CON – шорт ниже минимума премаркета<br/>
Оригинал статьи: <noindex><a href="http://shark-traders.com/blog/analitika-nyse-na-5-sentyabrya/" rel="nofollow">shark-traders.com/blog/analitika-nyse-na-5-sentyabrya/</a></noindex></div>
</div>
Спайдер повышается перед открытием торгов на NYSE.
Европейские индексы на отрицательной территории.
SPY (внутридневной график) рост движение на премаркете. Сопротивление: 166.20 Поддержка: 165.80
Премаркет NYSE/NASDAQ:
Gapping up:
• In reaction to stong earnings/guidance/SSS data: ENVI +28.6%, FCEL +15.4%, SIGM +9.1%, DDC +2.1%, COST +1.3%, WAG +1.3%.
• M&A news: KDN +21.3% (to be acquired by SKF for $35.50 per share), LPX +9.1% (to acquire Ainsworth for ~$1.1 bln, upgraded to Buy from Hold at Deutsche Bank, upgraded to Buy at DA Davidson), TI +8.1% (AT&T (T), American Movill (AMX), and Naguib Sawiris have approached key shareholders who want to exit stakes in TI, according to reports), BBRY +2.8% (following late spike on M&A speculation), ASTX +2.3% (Astex Pharma to be acquired by Otsuka Pharma for $8.50 per share in cash), VOD +1.8% (Dealbook discusses VZ's efforts to secure financing for Vodafone (VOD) deal), VZ +0.5%.
• Select India related names showing strength: HDB +6.3%, IBN +6%, TTM +2.7%.
• Other news: LOCM +39% (signs agreement with Microsoft (MSFT) to provide location-based local product data for Bing ), CLWT +18.7% (Reports Contract Awarded to PACT), MDXG +15.8% (following yesterday's sell-off; to hold conference call to discuss FDA 'Untitled Letter' and reiterate guidance on Thursday, September 5, 2013 at 11 am Eastern Time ), POZN +15.3% (POZEN and Sanofi (SNY) sign exclusive licence agreement for the commercialization of PA8140/PA32540 tablets in the U.S.), CHTP +6.8% (announces FDA Acceptance of NORTHERA (droxidopa) NDA Resubmission), IDCC +5.6% (related to ITC decision to review ruling in case against Nokia and other parties), HIMX +5.4% (target raised to $12 at Oppenheimer on better LCoS outlook), ALU +3.6% (reached an agreement with Telefonica, to become a reference supplier for its 4G LTE network in Spain), AU +2.3% (still checking), MRLN +2.1% (Declares Special Dividend of $2.00/share), NOK +1.9% (still checking, was resumed with an Equal-Weight at Morgan Stanley), CELG +1.5% (reports postive results from from Phase III study).
• Analyst comments: OVAS +6.2% (initiated with and Outperform at Wedbush), GRPN +5.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), YY +4.1% (upgraded to Outperform at Pacific Crest; tgt $52), ONB +2% (upgraded to Strong Buy from Outperform at Raymond James), SI +1.6% (upgraded to Overweight from Equal-Weight at Barclays), RIG +1.5% (upgraded to Outperform from Neutral at Credit Suisse), OMC +1.1% (upgraded to Buy from Neutral at Lazard), GMCR +0.9% ( tgt to $95 from $89 at Canaccord Genuity).
Gapping down:
• In reaction to disappointing earnings/guidance/SSS: CONN -12.3%, NCS -11.7%, BV -10.2%, EXA -8.2%, (thinly traded), MIND -7.2%, TITN -5.1%, GEF -4.8%.
• Other news: AGEN -33.8% (GlaxoSmithKline's (GSK) MAGE-A3 Cancer Immunotherapeutic Phase 3 study in melanoma misses first co-primary endpoint), CPRX -7.2% (Registration Statement filed for additional $2,612,336 aggregate maximum principal amount of common stock), LNKD -1.8% (prices 5,381,166 shares of Class A common stock at $223.00 per share), CCL -1% (cont weakness), GSK -1% ( independent analysis of the DERMAi study showed that the study did not meet its first co-primary endpoint).
• Analyst comments: Z -2.5% (downgraded to Underweight from Equal-Weight at Morgan Stanley), E -1.0% (downgraded to Neutral from Buy at Nomura).
Интересные новостные акции NYSE и NASDAQ:
• FRAN – смотрим акцию на разворот выше 18.00
• LNKD – шорт ниже 234.00
• LPX – шорт ниже 16.40
• CON – шорт ниже минимума премаркета
Оригинал статьи: shark-traders.com/blog/analitika-nyse-na-5-sentyabrya/
Код для вставки в блог
5 сентября 2013, 16:52
Европейские индексы на отрицательной территории.
SPY (внутридневной график) рост движение на премаркете. Сопротивление: 166.20 Поддержка: 165.80
Премаркет NYSE/NASDAQ:
Gapping up:
• In reaction to stong earnings/guidance/SSS data: ENVI +28.6%, FCEL +15.4%, SIGM +9.1%, DDC +2.1%, COST +1.3%, WAG +1.3%.
• M&A news: KDN +21.3% (to be acquired by SKF for $35.50 per share), LPX +9.1% (to acquire Ainsworth for ~$1.1 bln, upgraded to Buy from Hold at Deutsche Bank, upgraded to Buy at DA Davidson), TI +8.1% (AT&T (T), American Movill (AMX), and Naguib Sawiris have approached key shareholders who want to exit stakes in TI, according to reports), BBRY +2.8% (following late spike on M&A speculation), ASTX +2.3% (Astex Pharma to be acquired by Otsuka Pharma for $8.50 per share in cash), VOD +1.8% (Dealbook discusses VZ's efforts to secure financing for Vodafone (VOD) deal), VZ +0.5%.
• Select India related names showing strength: HDB +6.3%, IBN +6%, TTM +2.7%.
• Other news: LOCM +39% (signs agreement with Microsoft (MSFT) to provide location-based local product data for Bing ), CLWT +18.7% (Reports Contract Awarded to PACT), MDXG +15.8% (following yesterday's sell-off; to hold conference call to discuss FDA 'Untitled Letter' and reiterate guidance on Thursday, September 5, 2013 at 11 am Eastern Time ), POZN +15.3% (POZEN and Sanofi (SNY) sign exclusive licence agreement for the commercialization of PA8140/PA32540 tablets in the U.S.), CHTP +6.8% (announces FDA Acceptance of NORTHERA (droxidopa) NDA Resubmission), IDCC +5.6% (related to ITC decision to review ruling in case against Nokia and other parties), HIMX +5.4% (target raised to $12 at Oppenheimer on better LCoS outlook), ALU +3.6% (reached an agreement with Telefonica, to become a reference supplier for its 4G LTE network in Spain), AU +2.3% (still checking), MRLN +2.1% (Declares Special Dividend of $2.00/share), NOK +1.9% (still checking, was resumed with an Equal-Weight at Morgan Stanley), CELG +1.5% (reports postive results from from Phase III study).
• Analyst comments: OVAS +6.2% (initiated with and Outperform at Wedbush), GRPN +5.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley), YY +4.1% (upgraded to Outperform at Pacific Crest; tgt $52), ONB +2% (upgraded to Strong Buy from Outperform at Raymond James), SI +1.6% (upgraded to Overweight from Equal-Weight at Barclays), RIG +1.5% (upgraded to Outperform from Neutral at Credit Suisse), OMC +1.1% (upgraded to Buy from Neutral at Lazard), GMCR +0.9% ( tgt to $95 from $89 at Canaccord Genuity).
Gapping down:
• In reaction to disappointing earnings/guidance/SSS: CONN -12.3%, NCS -11.7%, BV -10.2%, EXA -8.2%, (thinly traded), MIND -7.2%, TITN -5.1%, GEF -4.8%.
• Other news: AGEN -33.8% (GlaxoSmithKline's (GSK) MAGE-A3 Cancer Immunotherapeutic Phase 3 study in melanoma misses first co-primary endpoint), CPRX -7.2% (Registration Statement filed for additional $2,612,336 aggregate maximum principal amount of common stock), LNKD -1.8% (prices 5,381,166 shares of Class A common stock at $223.00 per share), CCL -1% (cont weakness), GSK -1% ( independent analysis of the DERMAi study showed that the study did not meet its first co-primary endpoint).
• Analyst comments: Z -2.5% (downgraded to Underweight from Equal-Weight at Morgan Stanley), E -1.0% (downgraded to Neutral from Buy at Nomura).
Интересные новостные акции NYSE и NASDAQ:
• FRAN – смотрим акцию на разворот выше 18.00
• LNKD – шорт ниже 234.00
• LPX – шорт ниже 16.40
• CON – шорт ниже минимума премаркета
Оригинал статьи: